Effect of ipragliflozin on liver gene expression in HFD-fed WT mice.
Chikara Komiya
Kyoichiro Tsuchiya
Kumiko Shiba
Yasutaka Miyachi
Shunsaku Furuke
Noriko Shimazu
Shinobu Yamaguchi
Kazuo Kanno
Yoshihiro Ogawa
10.1371/journal.pone.0151511.g002
https://plos.figshare.com/articles/figure/Effect_of_ipragliflozin_on_liver_gene_expression_in_HFD-fed_WT_mice_/3961263
<p>Gene expression levels in the liver associated with (A) lipogenesis, β-oxidation, gluconeogenesis, and (B) inflammation after 4 weeks of the vehicle or ipragliflozin treatment. # <i>p</i> < 0.05, ## <i>p</i> < 0.01 vs SD/Veh; * <i>p</i> < 0.05, ** <i>p</i> < 0.01 vs HFD/Veh. <i>n</i> = 6–8.</p>
2016-03-15 00:23:02
epididymal
Type 2 Diabetic Patients Irrespective
ipragliflozin ameliorates obesity-associated inflammation
T 2DM hepatic steatosis
accumulation
SGLT 2 inhibitors
attenuating body weight reduction
Body Weight Reduction Type 2 diabetes mellitus
insulin resistance
body weight
SGLT 2 inhibitor ipragliflozin
NAFLD
increase energy intake
T 2DM
body weight reduction
Sodium-glucose cotransporter 2